Positron Emission Tomography Measurement of Tumor Metabolism and Growth: Its Expanding Role in Oncology
- 14 March 2006
- journal article
- review article
- Published by Springer Nature in Molecular Imaging & Biology
- Vol. 8 (3) , 141-150
- https://doi.org/10.1007/s11307-006-0039-2
Abstract
This work highlights the explosion and evolution of positron emission tomography (PET) for use in oncology research and clinical practice. 2-Deoxy-2-[F-18]fluoro-d-glucose (FDG)-PET is important in the staging of cancer, estimation of prognosis, and for its ability to predict therapeutic outcome. A number of new imaging agents are under development and may find a place in oncology when studies prove their utility. This scientific overview includes a review of the development of a number of thymidine analogs, such as 18F-3′-deoxy-3′-fluorothymidine (FLT) and 18F-1-(2′-deoxy-2′-fluoro-beta-d-arabinofuranosyl)-thymine (FMAU), including chemical structure variations; their application in a variety of tumors; and the role of various kinetic models for understanding cellular proliferation. The greatest unmet need for PET is in further developing and validating its use in the measurement of treatment response.Keywords
This publication has 59 references indexed in Scilit:
- CT Screening for Lung Cancer: Update 2005Surgical Oncology Clinics of North America, 2005
- Prognostic Significance of Preoperative [18-F] Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Imaging in Patients With Resectable Soft Tissue SarcomasAnnals of Surgery, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Synthesis of 2′-deoxy-2′-[18F]fluoro-β-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferationNuclear Medicine and Biology, 2003
- Synthesis of 2′‐[F‐18]fluoro‐2′‐DEOXY‐β‐D‐arabinofuranosyl nucleosidesJournal of Labelled Compounds and Radiopharmaceuticals, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Synthesis of 2′-fluoro-5-[11C]-methyl-1-β-d-arabinofuranosyluracil ([11C]-FMAU): A potential nucleoside analog for in vivo study of cellular proliferation with PETNuclear Medicine and Biology, 1995
- Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examinationBrain Research Reviews, 1982
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957